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Abstract
Introduction: Binding immunoglobulin protein (BiP) has previously shown powerful anti-inflammatory properties in
the collagen-induced arthritis (CIA) model, where a single dose of BiP has proved to be both a long-term prophylactic
and therapeutic. In both CIA and human in vitro studies, BiP induced regulatory T cells. The present investigation looked
at the anti-inflammatory effect of BiP on inflamed human synovial tissue transplanted into severe combined
immunodeficient mice (SCID), a chimaeric in vivo model previously used to test the efficacy of biologic therapies.
Methods: Rheumatoid arthritis synovial membrane (RASM) was engrafted into SCID mice. Following successful
engraftment, mice were intravenously injected with BiP or human serum albumin in the presence or absence of
anti-IL-10 mAb. Twelve days later the grafts were removed for analysis and human cytokines in the sera were
quantified by ELISA. The extent of residual inflammatory cellular infiltrate in the synovial explants was determined
by weight of the explants.
Results: The RASM transplants from mice treated with BiP showed visual reduction in cellular infiltrate and
downregulation of all quantifiable features of inflammation as assessed by the Koizumi or Rooney histological
criteria. Also downregulated were HLA-DR, CD86, IL-6 and TNFa expression as assessed by immunohistology. ELISA
detected significantly less human IL-6 circulating in the BiP-treated mouse serum. After removal of transplanted
tissue 12 days post administration of BiP, the RASM explants from the BiP-treated SCID mice weighed significantly
less, indicating a suppression of tissue inflammation. Mice given concomitant neutralising anti-IL-10 antibody and
BiP showed no such suppression.
Conclusions: BiP has anti-inflammatory properties partially dependent on the downregulation of HLA-DR and co-
stimulatory molecules and the predominant production of IL-10.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammation dis-
ease characterised by hypertrophy of the synovial mem-
brane, ultimately causing joint damage due, in part, to
the sustained production of inflammatory cytokines such
as TNFa, IL-1b and IL-6. We have previously shown that
binding immunoglobulin protein (BiP) downregulates
both immune and inflammatory responses in vitro in our
work with human peripheral blood mononuclear cells
[1], where it attenuates TNFa production and upregu-
lates production of IL-10, IL-1 receptor antagonist and
soluble TNF receptor II. Inv i v o ,u s i n gt h em u r i n e
collagen-induced arthritis( C I A )m o d e li ne i t h e rD B A / 1
or HLA-DR1
+/+ transgenic mice [2], BiP has long-lasting
prophylactic and therapeutic action. Importantly, the
immunoregulatory function of BiP is not dependent on
the continued presence of the protein, since adoptive
transfer of spleen and lymph node cells from BiP-treated
animals into mice with CIA could prevent or treat arthri-
tis without further administration of BiP [2].
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any medium, provided the original work is properly cited.Biologic therapies have been successfully used in the
therapy of RA over the past decade but a significant
number of patients fail to respond to their treatment [3].
BiP, however, has a different mechanism of action from
t h ec u r r e n t l ya v a i l a b l ea n t i b o d yt h e r a p i e s ,a se v i d e n t
from the long-term disease remission seen in animal stu-
d i e s[ 2 ] .A sap o s s i b l et h e r a p e u t i ca g e n ti nR A ,h o w e v e r ,
BiP requires further validation of its anti-arthritic proper-
ties. In vitro human studies have established that the
downregulation of HLA-DR and the co-stimulatory
molecule CD86 are sensitive biomarkers of BiP activity,
as is the rapid attenuation of TNFa production and
increase in IL-10 production [1]. Prior to clinical studies
it is necessary to confirm that these remain useful mar-
kers in a relevant model. We therefore chose a xeno-
geneic in vivo model involving transplant of human
rheumatoid arthritis synovial membrane (RASM) into
severe combined immunodeficient (SCID) mice. This
model has been validated previously as a robust screen
for therapeutic efficacy since anti-TNFa [4] and anti-
soluble IL-6 receptor [5] antibodies suppress inflamma-
tion in similar models.
Materials and methods
Preparation of recombinant human binding
immunoglobulin protein
BiP was prepared as previously described [6]. The pro-
tein purity, as assessed by polyacrylamide gel electro-
phoresis and silver staining, was greater than 95%.
Professional assessment of endotoxin contamination
showed < 0.3 endotoxin units/μg protein (Associates of
Cape Cod, Liverpool, UK).
Preparation of RASM/SCID mice
The RASM/SCID (CB.17/Icr; Charles River Japan, Tokyo,
Japan) murine model was set up as described [4]. All RA
patients providing tissue during knee joint replacement
surgery gave fully informed written consent and the study
was approved by the Research Ethics Committee of Toin
University of Yokohama Project approval number I-1.
Therapeutic manipulation of the mice was undertaken
only if successful engraftment had been achieved 4 weeks
after transplantation. BiP (10 μg/mouse, n = 15) or human
serum albumin (HSA) (10 μg/mouse, n = 15), as the con-
trol protein, were administrated intravenously either alone
or in the presence or absence of anti-IL-10 antibody or
isotype control antibody as required. The mice were sacri-
ficed 12 days later and implanted tissue was removed for
analysis by immunohistology and weight.
Scoring the degree of synovial inflammation and
inflammatory cell infiltrate
The degree of histological synovial inflammation of the
implanted tissue was assessed as described by Koizumi
and colleagues [7] or by Rooney and colleagues [8]. The
scoring features included measurements of synovial hyper-
plasia, fibrosis, blood vessels, perivascular lymphocytes,
lymphoid follicles, and diffuse infiltrating lymphocytes or
synovial cells, palisading, giant cells, lymphocytes, granular
tissue and fibrosis.
Immunohistological examination
Paraffin-embedded tissue sections were used for immu-
nostaining for CD86 and HLA-DR. Frozen tissue sections
were stained for the detection of cytokines (TNFa,I L - 6
and IL-10). The tissue sections were blocked for endo-
genous peroxidase activity with 0.3% hydrogen peroxide
in methanol. Nonspecific antibody binding was blocked
with 10% normal goat serum. The sections were incu-
bated with specific antibody or normal IgG for 1 hour at
37°C. The sections incubated with anti-CD86 or HLA-
DR antibody were treated with biotinylated secondary
antibody, and then visualised using the Vectastatin ABC
kit (Vector Laboratories, Funakoshi Co, Tokyo, Japan). A
visual scoring scale of 0 to 3 was used to assess the
expression of the molecules. The other sections were
treated with peroxidase-conjugated anti-mouse IgG (His-
tofine Simple Stain MAX PO; Nichirei, Tokyo, Japan)
developed with 3-amino-n-ethylcarbazole (Nichirei) for
visualisation. Sections were counterstained with Mayer
haematoxylin.
Measurement of human IL-4, IL-6 and IL-10 in mouse
serum
The serum levels of human IL-4, IL-6 and IL-10 were
measured by a quantitative sandwich enzyme immunoas-
say technique (Quantikine HS; R&D Systems, Funakoshi
Co Tokyo, Japan) according to the manufacturer’s
instructions.
Statistical analysis
Data were compared using the Student t test and
expressed as the mean ± standard deviation.
Results and discussion
It is difficult to extrapolate from data derived either from
animal models or in vitro human experiments to envisage
how a potential therapy will act in humans. Previously,
however, the RASM/SCID model has been used to predict
the success of biologic therapies currently being used in
the clinic for RA, such as anti-TNFa [4].
BiP abrogates inflammation in human RASM transplanted
into SCID mice
Twelve days following intravenous injection of BiP into
the RASM/SCID chimaeric mice, the histological fea-
tures of the RASM taken from the control mice were
u n c h a n g e d( F i g u r e1 a )c o m p a r e dw i t ht h em a r k e d l y
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BiP-treated mice (Figure 1b). Histopathogical measure-
ments of the RASM grafts from mice given intravenous
BiP showed that although there was not a complete
absence of inflammation it was significantly reduced
compared with grafts taken from control mice (overall
scores: Rooney, BiP 16 ± 6 vs. HSA 27 ± 8.2, P =0 . 0 0 6 ;
Koizumi, BiP 6.1 ± 2.6 vs. HSA 12 ± 2.2, P <0 . 0 0 1 ;B i P
n =1 5a n dH S An = 14) (Figure 1c and 1d, respec-
tively). The data from this experimental model confirm
that BiP acts in an anti-inflammatory fashion and they
predict a reduction in pathology in vivo.I n d e e d ,t h e
gross pathology following BiP treatment showed results
similar to those seen in the same model following
administration of anti-TNFa or anti-IL-6 receptor mAbs
[4,5] and also the disease-modifying drug methotrexate
[9].
BiP reduces antigen presentation and inflammatory
cytokines
Immunohistological assessment of the RASM tissue sec-
tions showed significantly reduced expression of the co-
stimulatory molecule CD86 (mean visual score ± stan-
dard error: HSA 1.86 ± 0.46, n =7v s .B i P0 . 8 9±0 . 3 5 ,
n =9 ;P = 0.05) and a trend to the downregulation of
HLA-DR (HSA 1.67 ± 0.37, n =9v s .B i P1 . 3 7±0 . 3 7 ,
n =8 ,P < 0.06 (NS)) (Figure 2a), thus reducing the
capacity for antigen presentation by monocytes/macro-
phages/dendritic cells. This observation complements
our in vitro data showing that BiP has a significant inhi-
bitory effect on HLA-DR expression and downregulates
CD86 expression by human peripheral blood monocytes
[1] and monocyte-derived dendritic cells [10]. One
mechanism of action by which BiP might reduce T-cell
activation, and thus inflammation, is therefore by
A
B
C
D
Figure 1 Binding immunoglobulin protein reduces gross pathology of synovial membrane transplants. Pieces of human synovial tissue
from patients with rheumatoid arthritis were transplanted into severe combined immunodeficient mice. After successful engraftment, binding
immunoglobulin protein (BiP) (10 μg/animal) or human serum albumin (HSA) (10 μg/animal) were administered intravenously, and 12 days later
the tissue was removed for immunohistological examination. Representative figures of haematoxylin-stained tissue removed from (a) HSA-treated
mice or (b) BiP-treated mice. Transplant samples were scored by (c) Rooney and colleagues’ and (d) Koizumi and colleagues’ histological criteria.
Results are the mean and standard deviation of 15 animals in each group. *P < 0.02 in a comparison of BiP-treated and HSA-treated samples.
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[1].
Additionally, a profound suppression of inflammatory
cytokines TNFa and IL-6 was noted in RASM retrieved
from the BiP-treated animals (Figure 2a). The suppres-
sion of TNFa in the RASM by BiP is particularly perti-
nent in diseased tissue where TNFa is known to be the
major inflammatory mediator, and gives credence to
such disease-related changes noted in in vitro human
peripheral blood mononuclear cell cultures.
Only human IL-6 was produced at levels detectable in
the sera of control mice injected with HSA, but not in the
sera of mice given intravenous BiP. There was a significant
reduction in background levels of circulating human IL-6
in these mice (HSA 1.13 ± 1.1 pg/ml vs. BiP 0.32 ± 0.13
pg/ml, P = 0.01) (Figure 2b). This is an important correla-
tion. Since IL-6 is a pleiotropic cytokine this inhibition
may have important consequences if translated to RA
patients receiving BiP, including: reduced stimulus for the
acute-phase response, leading to a reduction in C-reactive
protein and the erythrocyte sedimentation rate; inhibition
of development of Th17 cells, which are important proin-
flammatory cells in RA [11] for which IL-6 is a pre-requi-
site [12]; and downregulation of other pathogenic
mechanisms, such as osteoclast activity [13].
Addition of anti-IL-10 inhibits BiP function
Although BiP stimulates the production of IL-10 from
peripheral blood mononuclear cells in vitro [1], we
lacked histological evidence for the upregulation of
IL-10 protein in the BiP-treated RASM/SCID mouse.
This may have been due to the single time-point chosen
for the experiment. To test the hypothesis that the ther-
apeutic effect of BiP was at least partially mediated via
IL-10, BiP or HSA were therefore simultaneously admi-
nistered with either a neutralising anti-IL-10 antibody or
an isotype antibody control.
The weight of the transplant was used as a surrogate
measure of inflammation. Weight loss, indicative of the
loss of inflammatory cells and reduced tissue oedema,
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Figure 2 Binding immunoglobulin protein treatment alters cell surface molecule expression and cytokine production.B i n d i n g
immunoglobulin protein (BiP) treatment alters HLA-DR and co-stimulatory molecule expression and cytokine production in the xenogeneic
model of synovial membrane from rheumatoid arthritis patients transplanted into severe combined immunodeficient (SCID) mice. Pieces of
human synovial tissue from patients with rheumatoid arthritis were transplanted into SCID mice. After successful engraftment, BiP (10 μg/animal)
or human serum albumin (HSA) (10 μg/animal) were administered intravenously, and 12 days later tissue and serum were removed for analysis.
(a) Representative immunohistology photomicrographs showing explants of synovial membrane taken from mice injected with HSA (left) or
from mice injected with BiP (right). (b) Scattergram showing the concentration of human cytokines IL-4, IL-6 or IL-10 detected in the sera of
mice given either HSA or BiP, as detected by ELISA. Each group contained 15 animals.
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from the mice given HSA, whether co-injected with the
anti-IL-10 antibody or the isotype control, did not differ in
w e i g h t( H S A+a n t i - I L - 1 0 ,0 . 3 3±0 . 0 6g ;H S A+i s o t y p e ,
0.27 ± 0.07 g; P = NS). In contrast, the explants from the
mice given BiP + isotype control were significantly lighter
in weight from those explants given anti-IL-10 (BiP + iso-
type control, 0.07 ± 0.04 g vs. BiP + anti-IL-10, 0.26 ± 0.04
g; n =4 ,P = 0.007) (Figure 3). Importantly, there was no
difference in weight between the two HSA groups and the
group given BiP + anti-IL-10 (Figure 3). These data pro-
vide indirect evidence of IL-10 involvement. Undoubtedly
the production of IL-10 facilitates the attenuation of
TNFa production [1], but data also indicate that the posi-
tive deactivation of monocytes [14] is important for the
immunomodulatory effect of BiP, with downregulation of
CD86 and HLA-DR and upregulation of soluble TNF
receptor II and IL-1 receptor antagonist production [1].
These latter functions may be independent of IL-10 pro-
duction [1,15]. It is certainly evident that, although BiP
and IL-10 have a similar effect on monocytes, the kinetics
are different [1] - therefore, at present, the extent to which
IL-10 defines BiP activity is unclear.
Consideration should also be given to the extended
activity of BiP treatment in the absence of protein. In
vivo adoptive transfer experiments clearly indicate that
the induction of regulatory T cells is important [2], and
the identification of the regulatory cell subpopulation
involved is currently under investigation. Likewise, the
BiP-induced attenuation of IL-6 is a novel finding from
this model and we are presently investigating this in
relation to BiP.
Conclusions
A single systemic administration of BiP in the RASM/
SCID model post engraftment of the RASM suppressed
all gross markers of pathology as recorded by Rooney
and colleagues and by Koizumi and colleagues. In addi-
tion, CD86 and HLA-DR expression was reduced and IL-
6a n dT N F a production was attenuated. Evidence thus
suggests that BiP resolves RASM inflammation and that
this is at least in part a consequence of IL-10 production.
The study confirms that BiP has long-term anti-inflam-
matory and immunomodulatory properties in vivo. There
is therefore a reasonable expectation that BiP may prove
to be an effective immunotherapy for RA acting by an
entirely novel mechanism.
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inflammation. The results of four animals in each group are shown.
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